Hybio Pharmaceutical Market Cap ($2.94 Billion)
Market Cap & Net Worth: Hybio Pharmaceutical (300199)
Hybio Pharmaceutical market cap. Hybio Pharmaceutical (SHE:300199) has a market capitalization of $2.94 Billion (CN¥20.06 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #4847 globally and #760 in its home market, demonstrating a -2.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hybio Pharmaceutical's stock price CN¥22.71 by its total outstanding shares 883241336 (883.24 Million). Also see 300199 cash flow conversion for how efficiently the company converts equity into cash flow.
Hybio Pharmaceutical Market Cap History (2015–2026)
Hybio Pharmaceutical market cap history from 2015 to 2026. Data shows growth from $3.12 Billion to $2.94 Billion (0.73% CAGR). Check today's stock price for Hybio Pharmaceutical for real-time trading data and today's change.
Hybio Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hybio Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Hybio Pharmaceutical to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.82x
Hybio Pharmaceutical's market cap is 2.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.12 Billion | $768.26 Million | $305.34 Million | 4.06x | 10.21x |
| 2016 | $2.28 Billion | $855.05 Million | $291.92 Million | 2.67x | 7.81x |
| 2017 | $2.08 Billion | $1.25 Billion | $329.72 Million | 1.67x | 6.30x |
| 2018 | $1.21 Billion | $1.26 Billion | -$340.78 Million | 0.95x | N/A |
| 2019 | $749.63 Million | $614.19 Million | -$884.77 Million | 1.22x | N/A |
| 2020 | $859.49 Million | $721.72 Million | -$609.43 Million | 1.19x | N/A |
| 2021 | $1.63 Billion | $735.97 Million | $30.81 Million | 2.21x | 52.90x |
| 2022 | $2.27 Billion | $704.32 Million | -$370.55 Million | 3.23x | N/A |
| 2023 | $1.76 Billion | $431.38 Million | -$513.88 Million | 4.07x | N/A |
| 2024 | $1.67 Billion | $590.20 Million | -$173.65 Million | 2.82x | N/A |
Competitor Companies of 300199 by Market Capitalization
Companies near Hybio Pharmaceutical in the global market cap rankings as of November 5, 2026. Also see Hybio Pharmaceutical asset portfolio for a full breakdown of the balance sheet.
Key companies related to Hybio Pharmaceutical by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Hybio Pharmaceutical (2015–2026)
Market capitalization of Hybio Pharmaceutical from 2015 to today. Between 2015 and today, Hybio Pharmaceutical's market cap moved from $3.12 Billion to $ 2.94 Billion, with a yearly change of 0.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.94 Billion | +26.87% |
| 2025 | CN¥2.31 Billion | +38.87% |
| 2024 | CN¥1.67 Billion | -5.08% |
| 2023 | CN¥1.76 Billion | -22.75% |
| 2022 | CN¥2.27 Billion | +39.41% |
| 2021 | CN¥1.63 Billion | +89.62% |
| 2020 | CN¥859.49 Million | +14.66% |
| 2019 | CN¥749.63 Million | -37.90% |
| 2018 | CN¥1.21 Billion | -41.88% |
| 2017 | CN¥2.08 Billion | -8.86% |
| 2016 | CN¥2.28 Billion | -26.90% |
| 2015 | CN¥3.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Hybio Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.94 Billion USD |
| MoneyControl | $2.94 Billion USD |
| MarketWatch | $2.94 Billion USD |
| marketcap.company | $2.94 Billion USD |
| Reuters | $2.94 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as dis… Read more